Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Shares Outstanding (Diluted Average) (2016 - 2025)

Neurocrine Biosciences' Shares Outstanding (Diluted Average) history spans 16 years, with the latest figure at $102.5 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) fell 1.16% year-over-year to $102.5 million; the TTM value through Dec 2025 reached $102.5 million, down 1.16%, while the annual FY2025 figure was $102.5 million, 1.16% down from the prior year.
  • Shares Outstanding (Diluted Average) reached $102.5 million in Q4 2025 per NBIX's latest filing, roughly flat from $102.5 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $104.3 million in Q3 2024 to a low of $95.4 million in Q2 2022.
  • Average Shares Outstanding (Diluted Average) over 5 years is $100.3 million, with a median of $100.4 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): rose 6.69% in 2024, then dropped 2.7% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $97.9 million in 2021, then increased by 1.02% to $98.9 million in 2022, then increased by 2.12% to $101.0 million in 2023, then grew by 2.67% to $103.7 million in 2024, then dropped by 1.16% to $102.5 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Shares Outstanding (Diluted Average) are $102.5 million (Q4 2025), $102.5 million (Q3 2025), and $101.0 million (Q2 2025).